Direct Cytosolic Delivery of siRNA Conjugates: A Paradigm in Antiangiogenic Therapy for Choroidal Neovascularization
ACS Nano · 25.03.2025 · 19 (11) · 11249-11262
DOI: 10.1021/acsnano.4c18924 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, online erschienen am 12.03.2025. Verfasst von Tongqi Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No. 100 Haining Road, Shanghai 200080, Chin…. Hauptthemen laut MEDLINE: RNA, Small Interfering, Choroidal Neovascularization, Cytosol, Angiogenesis Inhibitors. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Liaoning Province Science and Technology Plan Joint Program.
Abstract (Originalsprache)
Small interfering RNA (siRNA) has garnered tremendous interest as a potential therapeutic tool because of its intriguing gene-silencing ability. Toward the success in the manufacture of siRNA therapeutics for the potential treatment of choroidal neovascularization (CNV), siRNA conjugated with dual functional units of membrane-penetrating heptafluoropropyl and age-related macular degeneration-targeting cyclic Arg-Gly-Asp (RGD) peptide was attempted for transcellular transportation into the cell interiors. Of note, cyclic RGD allowed selective affinities toward the angiogenic endothelial cells in the pathological CNV. Noteworthy is the functional heptafluoropropyl group, due to its tempting lipophobic and hydrophobic properties, stimulating energy-independent transcellular trafficking behaviors to the cytoplasm directly from the extracellular compartments, namely, the nonendocytotic pathway. The behaviors manage to avoid the well-acknowledged drawback of endolysosomal entrapment, which is deemed to be the critical threat to the biovulnerable genomic therapeutics, thereby contributing to potent gene knockdown at the affected cells. Aiming for treatment of CNV, the siRNA duo was schemed with appropriate chemistry-based modifications for the targeted knockdown of both angiogenic VEGF-A and VEGF-R2. Subsequent investigations verified the potent reduction of vascular leakage, and our proposed siRNA duo accomplished a significant reduction of 67.3% in the mean area of the CNV lesion. Bioinformatic analysis has unveiled a multitude of therapeutic benefits conferred by anti-VEGF therapy, extending beyond the mere inhibition of angiogenesis, including the regulated leukocyte transendothelial migration, retinol metabolism, and estrogen signaling pathways. Hence, our proposed chemistry represents an interesting siRNA conjugate strategy accomplishing direct intracellular transportation of macromolecular biological payloads to the cytosol. Hence, this proposed fluorination strategy should be highlighted to encourage the development of appropriate prodrug chemistry in pursuit of transcellular trafficking of membrane-impermissible and biovulnerable biotherapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No. 100 Haining Road, Shanghai 200080, China.
- Department of Gastric Surgery, Cancer Hospital of China Medical University, No. 44 Xiaoheyan Road, Dadong District, Shenyang 110042, China.
- Department of Gastric Surgery, Cancer Hospital of Dalian University of Technology, No. 44 Xiaoheyan Road, Dadong District, Shenyang 110042, China.
- Provincial Key Laboratory of Interdisciplinary Medical Engineering for Gastrointestinal Carcinoma, Liaoning Cancer Hospital & Institute, No. 44 Xiaoheyan Road, Dadong District, Shenyang 110042, China.
- School of Public Health, Dalian Medical University, No. 9 West Section Lvshun South Road, Dalian 116044, China.
- Innovation Center of Yangtze River Delta, Zhejiang University, Jiaxing 314100, China.
ORCID-Profile: Liuwei Zhang, Jin Wang, Qixian Chen
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Liaoning Province Science and Technology Plan Joint Program
- Liaoning Talent Program-Medical Expert Project
- Zhejiang Provincial Natural Science Foundation of China
- Clinical Research Fund of Wu Jieping Medical Foundation
- Shanghai Sailing Program
Zitieren
APA
Li, T., Wang, Y., Chen, X., Cui, H., Zhang, L., Liu, J., Wang, J., Wang, X., Zhao, Y., Chen, Q., & Wang, J. (2025). Direct Cytosolic Delivery of siRNA Conjugates: A Paradigm in Antiangiogenic Therapy for Choroidal Neovascularization. ACS Nano, 19(11), 11249-11262. https://doi.org/10.1021/acsnano.4c18924
Vancouver
Li T, Wang Y, Chen X, Cui H, Zhang L, Liu J, et al. Direct Cytosolic Delivery of siRNA Conjugates: A Paradigm in Antiangiogenic Therapy for Choroidal Neovascularization. ACS Nano. 2025;19(11):11249-11262. doi:10.1021/acsnano.4c18924
BibTeX
@article{Li2025,
author = {Li, Tongqi and Wang, Yue and Chen, Xiyi and Cui, Hongyan and Zhang, Liuwei and Liu, Jun and Wang, Jin and Wang, Xiumei and Zhao, Yan and Chen, Qixian and Wang, Jing},
title = {Direct Cytosolic Delivery of siRNA Conjugates: A Paradigm in Antiangiogenic Therapy for Choroidal Neovascularization},
journal = {ACS Nano},
year = {2025},
volume = {19},
number = {11},
pages = {11249--11262},
doi = {10.1021/acsnano.4c18924}
}
EUVIMED